Lecture: Clinical trials in T2DM & CVD: Review of key outcomes with GLP-1 RA and SGLT2i

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits
Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits
CDMC 2018: Shifting gears in the management of diabetes and CVD
Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits
- Dr. Adie Viljoen, MD
Lecture: Screening for Diabetes: When is it meaningful and how should it be performed
Lecture: Screening for Diabetes: When is it meaningful and how should it be performed
CDMC 2018: Shifting gears in the management of diabetes and CVD
Lecture: Screening for Diabetes: When is it meaningful and how should it be performed
- Prof. Lars Rydén
Lecture: The GLP1 landscape - refining our understanding
Lecture: The GLP1 landscape - refining our understanding
CDMC 2018: Shifting gears in the management of diabetes and CVD
Lecture: The GLP1 landscape - refining our understanding
Lecture: Targeting CV risk: Implications for clinical management of patients with T2DM & CVD
Lecture: Targeting CV risk: Implications for clinical management of patients with T2DM & CVD
CDMC 2018: Shifting gears in the management of diabetes and CVD
Lecture: Targeting CV risk: Implications for clinical management of patients with T2DM & CVD
- Prof. Richard Hobbs, MD